Payne, January2022-07-292022-07-292022-07-26http://hdl.handle.net/10713/19476The Centers for Disease Control and Prevention (CDC) this week recommended a new COVID-19 protein-based vaccine as an option for primary vaccination of adults aged 18 and older. The University of Maryland School of Medicine’s (UMSOM) Karen Kotloff, MD, professor of pediatrics, medicine, epidemiology, and public health, co-led the multi-center PREVENT-19 clinical trial, which studied the safety and efficacy of the Novavax vaccine in about 30,000 adult study participants.en-USNovavaxCOVID-19 (Disease)Kotloff, KarenCOVID-19 VaccinesClinical TrialArticle